دورية أكاديمية
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibition in Kidney Transplant Recipients with Diabetes Mellitus
| العنوان: | Sodium-Glucose Cotransporter 2 (SGLT2) Inhibition in Kidney Transplant Recipients with Diabetes Mellitus |
|---|---|
| المؤلفون: | Moritz Mahling, Anja Schork, Silvio Nadalin, Andreas Fritsche, Nils Heyne, Martina Guthoff |
| المصدر: | Kidney & Blood Pressure Research, Pp 1-9 (2019) |
| بيانات النشر: | Karger Publishers, 2019. |
| سنة النشر: | 2019 |
| المجموعة: | LCC:Dermatology LCC:Diseases of the circulatory (Cardiovascular) system LCC:Diseases of the genitourinary system. Urology |
| مصطلحات موضوعية: | Kidney transplantation, Diabetes mellitus, Sodium-glucose cotransporter 2 inhibition, Empagliflozin, Renal and cardiovascular endpoints, Dermatology, RL1-803, Diseases of the circulatory (Cardiovascular) system, RC666-701, Diseases of the genitourinary system. Urology, RC870-923 |
| الوصف: | Background: Sodium-glucose cotransporter 2 (SGLT2) inhibition has been shown to reduce cardiovascular mortality and preserve kidney function in patients with type 2 diabetes. Kidney transplant recipients with diabetes demonstrate increased risk and accelerated progression of micro- and macrovascular complications and may specifically benefit from SGLT2 inhibition. However, potential concerns of SGLT2 inhibition include volume depletion and urinary tract infections. Objectives: We report data on the use of SGLT2 inhibitors in a case series of ten patients with diabetes after kidney transplantation in order to analyze efficacy, safety, and the effect on renal function. Methods: Patients with a stable allograft function and no history of recurrent urinary tract infections were eligible. The SGLT2 inhibitor empagliflozin was given as add-on to preexisting antidiabetic treatment with initial dose reduction of the latter. Results: Median estimated glomerular filtration rate at baseline was 57 mL/min/1.73 m2 and remained stable throughout the follow-up of 12.0 (5.3–12.0) months. Median HbA1c decreased from 7.3 to 7.1%. The rate of urinary tract infections and other side effects was low. Conclusions: SGLT2 inhibition is feasible and well tolerated in selected kidney transplant recipients with diabetes. Whether SGLT2 inhibition is able to reduce cardiovascular mortality and improve allograft survival in these patients has to be addressed in further studies. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 1420-4096 1423-0143 |
| العلاقة: | https://www.karger.com/Article/FullText/501854Test; https://doaj.org/toc/1420-4096Test; https://doaj.org/toc/1423-0143Test |
| DOI: | 10.1159/000501854 |
| الوصول الحر: | https://doaj.org/article/5f70578dd736464a978d5e0fbf1f78ecTest |
| رقم الانضمام: | edsdoj.5f70578dd736464a978d5e0fbf1f78ec |
| قاعدة البيانات: | Directory of Open Access Journals |
| تدمد: | 14204096 14230143 |
|---|---|
| DOI: | 10.1159/000501854 |